Kairos Pharma’s Investigational New Drug (IND) application to commence a Phase I clinical trial of its therapy KROS 201 for treating glioblastoma was okayed by the US Food and Drug Administration (FDA).
KROS 201 activated T cells (ATCs) are killer T cells created in a cell culture by stimulating white blood cells of a patient with cytokines or T cell activating signals and by coating glioblastoma cancer stem cell-specific antigens on dendritic cells.
Go deeper with GlobalData
The potent activated T cells are administered through intravenous infusion to individuals with recurrent glioblastoma.
Kairos noted that these cells have demonstrated to destroy cancer stem cells, which are the key root cause of cancer.
Sponsored by Kairos Pharma, the Phase I trial of KROS 201 in recurrent glioblastoma patients will be initiated at Cedars Sinai Medical Center in Los Angeles, US this year.
Kairos CEO John Yu said: “This IND acceptance is the second substantial clinical milestone within the past month as Kairos accelerates toward its clinical goals for 2022.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This first-in-man Phase I clinical trial will activate T cells against the cancer stem cells at the root of glioblastoma.”
The company also obtained a patent covering the method of treating fibrosis and certain cancer types, the composition of matter and administering a therapy using KROS-401.
KROS-401 is a cyclic peptide IL-4 and IL-13 cytokine receptor complex inhibitor and showed to treat fibrosis and cancer.
In February this year, the company obtained IND clearance from the FDA for a Phase II trial of ENV105 plus apalutamide to treat metastatic castration-resistant prostate cancer.
Furthermore, a Phase I trial of ENV105 plus AstraZeneca’ Tagrisso for the treatment of lung cancer is anticipated to being this year.
